AzTrials
AzTrials

CardiomyopathyDRTCNCT01067209

Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery

An observational study of Cardiomyopathy, run by Washington University School of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The overall purpose of this study is to evaluate the effect of gastric bypass surgery-induced weight loss on the heart's function and on fat deposits in the heart muscle. Read more about this study

Who is it for?
Ages 35 to 70 years
Conditions the study is for
Cardiomyopathy
How many people
18 participants
Where
1 siteUnited States
Study dates
Jan 2010to 14 Feb 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Obese patients +/- known diabetes who will undergo gastric bypass surgery.

Who may be able to join

  • All subjects will have type 2 diabetes or be at risk for type 2 diabetes and have a BMI>30kg/m2.
  • Subjects must be between the ages of 35 and 70 years, in order to limit the confounding affect of age on our endpoints.
  • 23 Subjects must also meet the following definition of diastolic dysfunction:
  • 1) meet Framingham criteria for heart failure (see Appendix),
  • 2) have an ejection fraction >45% based on the rest portion of the screening echocardiography,
  • 24 To determine if potential subjects meet these criteria, they will
Show all 9Show fewer
  • 1) be interviewed,
  • 2) their clinical charts reviewed, by the research study coordinator and/or the PI, and
  • 3) undergo a history and physical by the PI (Study Day 2) and undergo screening studies.

Who cannot join

  • Subjects who are <35 or >70 years,
  • current smokers, not obese,
  • unstable,
  • not able to lie flat for the imaging studies,
  • not ambulatory,
  • unable to give informed consent,
Show all 13Show fewer
  • pregnant, lactating will be excluded.
  • Those who have a condition that may masquerade as diastolic heart failure (e.g. constrictive pericarditis) will be excluded based on the screening echocardiogram;
  • those who have atrial flutter or fibrillation,
  • evidence of other major systemic diseases (e.g., cancer),
  • an ejection fraction <45%, >class I hypertension or who are taking more than 1 medication (other than a diuretic) for hypertension will be excluded.
  • We will not exclude patients with sleep apnea because data suggest it does not affect left ventricular (LV) diastolic function, but we will ask about it on a questionnaire for better phenotyping of the subjects.25
  • We will exclude patients with significant pulmonary hypertension (peak artery pressure>55mmHg), since most patients with diastolic dysfunction have a pressure lower than this, and a pressure greater than this may indicate other cardiopulmonary pathology.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Washington University School of Medicine

    St Louis, Missouri, 63110

Other trials in United States

About this study

Official title: Reversal of Obesity- and Diabetes-related Cardiomyopathy in Patients Who Have Undergone Gastric Bypass Surgery.

The overall purpose of this study is to evaluate the effect of gastric bypass surgery-induced weight loss on the heart's function and on fat deposits in the heart muscle.

Read the detailed description

Diabetes is a major risk factor for heart failure. Moreover, patients with diabetes and heart failure have a worse survival than those without diabetes. We know that patients with diabetes have altered heart metabolism, structure, and function. It is unclear if these alterations can be ameliorated with weight loss. We would like to learn whether cardiac metabolism, structure, and function in diabetic patients with heart failure symptoms can be improved with marked weight loss after gastric bypass surgery.

Study Day 1. Screening. We will screen subjects with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery. We will approach all patients at the Bariatric Surgery clinic regarding enrollment in our study. If they agree to participate, they will answer simple questionnaires re: medical history, obesity information, and MRI/MRS exclusion (see Appendices). We will obtain their permission to review their medical charts.

Study Day 2. Screening will include a physical examination and phlebotomy for a complete blood count, oral glucose tolerance test, \& comprehensive metabolic profile and a screening rest and stress echocardiogram. The rest and stress echocardiogram will be used to exclude cardiac abnormalities other than diastolic dysfunction. Optison™ or Definity will be used as needed for the echocardiograms. We will determine the subjects' fat and fat-free mass using dual-energy X-ray absorptiometry (DXA) imaging at the Center for Applied Research Sciences unit.

Study Day 3. Baseline Imaging Studies. Subject preparation. We expect 30 subjects to complete our study's screening tests and meet our study criteria. The evening before imaging Study Days 3 \& 4, subjects will be admitted to The Center for Applied Research Sciences Intensive Research Unit in order to standardize their metabolic milieu for their myocardial fat imaging studies. At 1800, subjects will ingest a standard meal containing a total of ~700 kcal for the subjects. Carbohydrate, fat, and protein will represent 55, 30, and 15%, respectively, of total energy intake. At 2000, subjects will ingest a defined liquid formula snack containing 250 kcal, 40 g carbohydrate, 6.1 g fat, and 8.8 g protein (Ensure, Ross Laboratories, Columbus, OH). After this snack, all subjects will fast until completion of the study the following day. Subjects will be given a lunch after completing their imaging studies. Magnetic resonance imaging (MRI). Subjects will be placed in the gantry of the scanner. Examinations will be performed on the 1.5T scanner using ECG gating, breath-hold, and a chest array coil This same scanner will be used for 1H-Magnetic resonance spectroscopy (MRS). The MRS protocol is based on a free-breathing, point-resolved spectroscopy (PRESS) sequence with both ECG and two-dimensional respiratory gating optimized for accuracy and robustness. Subject care. All subjects will be given a lunch, prepared at the Intensive Research Unit after imaging is completed. All imaging should be completed by 12PM. If the physician monitoring the subject determines that the subject would benefit from furosemide 20mg, p.o. x 1, or KCl, p.o. - a 10 day course may be provided (with a follow-up K+ check). Patients' physicians would be notified of any changes. We request subjects stay on their same medical regimen throughout the testing period. We recognize that this may not be possible for all subjects.

Gastric bypass. Subjects will undergo surgery after Study Day 3. The same surgeon (J.C.E.) will perform all bypass procedures using standard techniques. Briefly, a small (~20 mL) proximal gastric pouch will be created by stapling across the stomach, and a 150 cm Roux-Y limb constructed by transecting the jejunum 30cm distal to the ligament of Treitz and creating a jejunojejunostomy 150 cm distal to the transection.

Study Day 4. Imaging Studies - 3 months after surgery. Subjects will undergo the same imaging studies under the same conditions and in the same order as on Study Day 3 except that subjects on Day 4 will also undergo a resting echocardiogram for diastolic function.

Conditions
Cardiomyopathy
Keywords
Reversal of Obesity-related and Diabetic Cardiomyopathy
Medical subject headings
Cardiomyopathies, Diabetic Cardiomyopathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01067209
Study groupRoleWhat they receive
Diabetic/Obese Gastric bypass patientsSubjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary outcome measure: cardiac function, myocardial fat deposition

    Measured: the time frame of the study

Secondary outcomes (1)
  1. Plasma lipidomics, liver fat deposition

    Measured: the time frame of the study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Feb 2010 (estimated)
  2. Study startJan 2010
  3. Primary completion14 Feb 2013
  4. Study completion14 Feb 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01067209
Sponsor's protocol ID
09-1295
Acronym
DRTC
Status last verified
Jan 2024
First submitted
9 Feb 2010
Last updated
11 Jan 2024
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiomyopathy, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary outcome measure: cardiac function, myocardial fat deposition (time frame: the time frame of the study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in